학술논문
Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
Document Type
Academic Journal
Author
Fragoso YD; Department of Neurology, Universidade Metropolitana de Santos, Santos, SP, Brazil.; Adoni T; Department of Neurology, Hospital Sirio Libanes, Sao Paulo, SP, Brazil.; Alves-Leon SV; Department of Neurology, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.; Apostolos-Pereira SL; Department of Neurology, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.; Barreira AA; Department of Neurology, Universidade de Sao Paulo campus Ribeirao Preto, Ribeirao Preto, SP, Brazil.; Brooks JB; Department of Neurology, Universidade Metropolitana de Santos, Santos, SP, Brazil.; Claudino R; Department of Neurology, Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.; Correa EC; Department of Neurology, CLINEN, Brasilia, DF, Brazil.; Ferreira ML; Department of Neurology, Hospital da Restauracao, Recife, PE, Brazil.; Finkelsztejn A; Department of Neurology, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.; Finkelsztejn J; Department of Neurology, Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil.; da Gama PD; Department of Neurology, Pontificia Universidade Catolica Campus Sorocaba, Sorocaba, SP, Brazil.; Goncalves MV; Department of Neurology, Centro Hospitalar Unimed, Joinville, SC, Brazil.; Guerreiro CT; Department of Neurology, Universidade de Sao Paulo campus Ribeirao Preto, Ribeirao Preto, SP, Brazil.; da Cunha Matta AP; Department of Neurology, Universidade Federal Fluminense, Niteroi, RJ, Brazil.; Marques VD; Department of Neurology, Universidade de Sao Paulo campus Ribeirao Preto, Ribeirao Preto, SP, Brazil.; Rizo Morales R; Department of Neurology, Universidade Federal de Uberlandia, Uberlandia, MG, Brazil.; Parolin MF; Department of Neurology, Neurology Clinic, Curitiba, PR, Brazil.; de Castro Ribeiro M; Department of Neurology, Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, RS, Brazil.; Ribeiro TA; Department of Neurology, Universidade Federal de Goias, Goiania, Brazil.; Ruocco HH; Department of Neurology, Faculdade de Medicina de Jundiai, Jundiai, SP, Brazil.; Sato H; Department of Neurology, Neurological Institute Curitiba, Curitiba, PR, Brazil.; Scherpenhuijzen S; Department of Neurology, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.; Siquineli F; Department of Neurology, Universidade Regional de Blumenau, Blumenau, SC, Brazil.; de Carvalho Sousa NA; Department of Neurology, Hospital Universitario Getulio Vargas, Manaus, AM, Brazil.; Varela DL; Department of Neurology, Servico de Neurologia e Neurocirurgia de Passo Fundo, Passo Fundo, RS, Brazil.; Tauil CB; Department of Neurology, Hospital de Base do Distrito Federal, Brasilia, DF, Brazil.; Winckler TC; Department of Neurology, Universidade Positivo, Curitiba, PR, Brazil.
Source
Publisher: IOS Press Country of Publication: Netherlands NLM ID: 9113791 Publication Model: Print Cited Medium: Internet ISSN: 1878-6448 (Electronic) Linking ISSN: 10538135 NLM ISO Abbreviation: NeuroRehabilitation Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Fampridine is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to ameliorate conduction in demyelinated axons, thereby leading to improved gait in patients with multiple sclerosis (MS).
Objective: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group.
Methods: Patients with MS and gait disorders were prescribed fampridine (10 mg twice a day), irrespectively of the degree of disability determined by MS. Neurological disability determined by MS was assessed with the expanded disability scale score (EDSS). Outcomes for efficacy and safety of the drug were evaluated by the 25 foot-walk test and by the adverse events of fampridine.
Results: The time taken to walk 25 feet decreased by 20% or more in 62 patients (70%). Twenty-five patients were considered to be non-responders to this treatment. Improvement in walking speed was independent of improvement of disability. Mild or moderate adverse events were reported in 8% of patients.
Conclusion: Fampridine is an efficient and safe therapeutic option for patients with MS and gait disorders.
Objective: To assess the "real-life" efficacy and safety of fampridine prescribed for gait disorders in MS. This was an observational and prospective study carried out at MS Units participating in the Brazilian Multiple Sclerosis Study Group.
Methods: Patients with MS and gait disorders were prescribed fampridine (10 mg twice a day), irrespectively of the degree of disability determined by MS. Neurological disability determined by MS was assessed with the expanded disability scale score (EDSS). Outcomes for efficacy and safety of the drug were evaluated by the 25 foot-walk test and by the adverse events of fampridine.
Results: The time taken to walk 25 feet decreased by 20% or more in 62 patients (70%). Twenty-five patients were considered to be non-responders to this treatment. Improvement in walking speed was independent of improvement of disability. Mild or moderate adverse events were reported in 8% of patients.
Conclusion: Fampridine is an efficient and safe therapeutic option for patients with MS and gait disorders.